Fig. 1
The neutralization and ACE2 competition potency of 5 mAbs against SARS-CoV-2 and its variants. A The viruses were mixed with mAbs (a twofold serial dilution), incubated for 2 h, and subsequently cocultured with Vero cells for 4 days. Quadruplicates of each dilution were performed. Cytopathogenic effects of viral infection were visually scored for each well. The results were transformed into the percentage of neutralization at a particular monoclonal antibody concentration. The half-maximal inhibitory concentration (IC50) was plotted as a four-parameter dose–response curve using GraphPad Prism 8.0.2 software. The dotted line represents the concentration of 5 μg/mL. B Comparisons of the biotinylated human ACE2 protein and mAbs binding to S proteins of SARS-CoV-2 variants measured using ELISA. The IC50 values of mAbs against S proteins of SARS-CoV-2 variants are presented. The dotted line represents the concentration of 15 μg/mL